We are live on
!
Find out more
PVMCV
Polaris Venture Management Co V Portfolio holdings
AUM
$14.1M
1-Year Est. Return
121.41%
This Fund
S&P 500
This Quarter
Est. Return
+42.48%
1 Year Est. Return
+121.41%
3 Year Est. Return
+281.18%
5 Year Est. Return
+1,023.01%
10 Year Est. Return
–
AUM
$118M
AUM Growth
+$24.5M
(+26%)
Cap. Flow
-$4.42M
Cap. Flow
% of AUM
-3.74%
Top 10 Holdings %
Top 10 Hldgs %
99.23%
Holding
12
New
–
Increased
1
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cartesian Therapeutics
RNAC
|
+$2.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fate Therapeutics
FATE
|
+$5.52M |
| 2 |
Neuronetics
STIM
|
+$1.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.95% |
| 2 | Communication Services | 35.95% |
Similar funds
IFC
AG
RCM
IR
CCM
EIP
AAM
OEP
Polaris Venture Management Co V's Q1 2019 Portfolio in Review
As of Q1 2019, Polaris Venture Management Co V held 12 positions worth $118M, up 26% from $93.7M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Polaris Venture Management Co V withdrew a net $4.42M in Q1 2019, reducing 2 holdings. Its largest reduction was Fate Therapeutics, cutting an estimated $5.52M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 65% a quarter earlier, followed by Communication Services.
Against the trend, Polaris Venture Management Co V added an estimated $2.46M to Cartesian Therapeutics.
- Polaris Venture Management Co V added most to Cartesian Therapeutics in Q1 2019, an estimated $2.46M increase.
- Polaris Venture Management Co V's biggest Q1 2019 reduction was Fate Therapeutics, cutting an estimated $5.52M.
- Polaris Venture Management Co V's ten largest holdings make up 99% of its $118M portfolio in Q1 2019.
- Polaris Venture Management Co V opened 0 new positions and closed 0 in Q1 2019.
- Polaris Venture Management Co V's portfolio value rose 26% quarter-over-quarter to $118M.
Based on Polaris Venture Management Co V's 13F filing for Q1 2019, filed 15 May 2019.